Tumor Genomic and Transcriptomic Analysis Integrated With Liquid Biopsy ctDNA Monitoring: Analytical Validation and Clinical Insights
Cancer Medicine · 2025
DOI: 10.1002/cam4.71465 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Nam H B Tran und 16 weiteren Autor:innen. Beteiligte Einrichtung: Medical Genetics Institute, Ho Chi Minh City, Vietnam. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Biomarkers, Tumor, Gene Expression Profiling, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gene Solutions.
Abstract (Originalsprache)
Background
Comprehensive genomic profiling (CGP) is a time‐ and tissue‐ efficient method to help guide precision oncology. To enhance the clinical utility of CGP, we investigated the performance of a novel strategy integrating tumor DNA and mRNA profiling, together with liquid biopsy ctDNA monitoring.
Methods
Genomic DNA and mRNA simultaneously extracted from 604 archived tissue samples of 12 cancer types were used. Tumor DNA was subjected to targeted sequencing using a 504‐gene panel with high‐density probes (HDP), and shallow whole genome sequencing to profile genomic biomarkers. mRNA transcriptome profiling was performed to further capture fusion variants, and to predict tissue of origin (TOO) using our ensemble model OriCUP, an algorithm trained on 9889 samples and independently validated on 731 samples. In a cohort of 55 metastatic lung cancer patients, longitudinal plasma ctDNA was analyzed using a hybrid tumor‐informed and tumor‐agnostic approach to predict progression‐free survival (PFS).
Results
Among all biomarkers, DNA sequencing using HDP achieved higher sensitivity than the standard panel design to identify copy number variations at chromosome‐, gene‐, and exon‐ levels. The detection rate of fusion variants using DNA sequencing alone was 20% lower than mRNA sequencing in reference samples, while the combination of both methods was essential to maximize fusion detection in clinical FFPE samples. For TOO, our OriCup model achieved prediction accuracy of 87.7% for primary tumors and 81.4% for metastatic tumors. In 55 lung cancer patients, ctDNA profiling identified additional 11.5% tumor‐agnostic actionable and resistance mutations. Patients having more than 50% ctDNA decrease from baseline were classified as molecular responders and showed significantly longer PFS than those classified as molecular non‐responders (HR = 9.42, 95% CI: 3.33–26.67, p < 0.0001, 12‐month PFS: 95.5% vs. 31.7%).
Conclusions
Comprehensive genomic and transcriptomic profiling could reliably unveil genetic details not provided by DNA‐only CGP. The integration of ctDNA detection further helped detect tumor‐agnostic mutations and monitor treatment response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Genetics Institute, Ho Chi Minh City, Vietnam.
- Gene Solutions, Ho Chi Minh City, Vietnam.
- Hanoi Oncology Hospital, Hanoi, Vietnam.
- University Medical Center of HCMC, Ho Chi Minh City, Vietnam.
- Bach Mai Hospital, Hanoi, Vietnam.
- Ha Noi Medical University, Hanoi, Vietnam.
ORCID-Profile: Lan N Tu
Förderung
- Gene Solutions
Zitieren
APA
Tran, N. H. B., Nguyen, T. H., Bui, V. Q., Le, V. T., Mai, T. K., Nguyen Hoang, V. A., Nguyen, T. A., Nguyen, M. D., Pham, H. H., Vo, T. T. L., Ngo, M. T. T., Nguyen, D. Q., Nguyen, D. S., Nguyen, H. N., Phan, M. D., Giang, H., & Tu, L. N. (2025). Tumor Genomic and Transcriptomic Analysis Integrated With Liquid Biopsy ctDNA Monitoring: Analytical Validation and Clinical Insights. Cancer Medicine. https://doi.org/10.1002/cam4.71465
Vancouver
Tran NHB, Nguyen TH, Bui VQ, Le VT, Mai TK, Nguyen Hoang VA, et al. Tumor Genomic and Transcriptomic Analysis Integrated With Liquid Biopsy ctDNA Monitoring: Analytical Validation and Clinical Insights. Cancer Medicine. 2025. doi:10.1002/cam4.71465
BibTeX
@article{Tran2025,
author = {Tran, Nam H B and Nguyen, Thien-Phuc Hoang and Bui, Vinh Quang and Le, Vu Thuong and Mai, Trong Khoa and Nguyen Hoang, Van-Anh and Nguyen, Tien Anh and Nguyen, Minh-Duc and Pham, Ha-Hieu and Vo, Tho Thi Le and Ngo, My T T and Nguyen, Du Quyen and Nguyen, Duy Sinh and Nguyen, Hoai-Nghia and Phan, Minh-Duy and Giang, Hoa and Tu, Lan N},
title = {Tumor Genomic and Transcriptomic Analysis Integrated With Liquid Biopsy ctDNA Monitoring: Analytical Validation and Clinical Insights},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71465}
}
EUVIMED